Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

Cardiac Magnetic Resonance Imaging in Hemodialysis Patients

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00548912

Enrollment

Registered

2007-10-24

Start date

2007-10-31

Completion date

2008-10-31

Last updated

2021-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, Chronic

Keywords

Kidney Failure, Chronic, Hemodialysis, Spironolactone

Brief summary

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass

Detailed description

Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.

Interventions

DRUGSpironolactone

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* hemodialysis patients

Exclusion criteria

* non compliance * hyperkalemia * pregnancy * expected survival less than 9 months

Design outcomes

Primary

Measure	Time frame
Left ventricular mass	9 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026